2022
P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION‐BASED ANALYSIS
Zeidan A, Mearns E, Ng C, Shah A, Lamarre N, Yellow‐Duke A, Alrawashdh N, Yang B, Cheng W, Bui C, Svensson A. P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION‐BASED ANALYSIS. HemaSphere 2022, 6: 661-662. DOI: 10.1097/01.hs9.0000845948.33476.47.Peer-Reviewed Original ResearchLarge population-based analysisPopulation-based analysisClinical outcomesHypomethylating agentMyelodysplasticPatients
2020
Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study
Goksu S, Khatib J, Goksu B, Wang R, Patel P, Vusirkala M, Cole S, Seyhanli A, Ozer M, Collins R, Chung S, Zeidan A, Madanat Y. Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140564.Peer-Reviewed Original ResearchNon-Hispanic blacksCause-specific survivalIncidence rate ratiosNon-Hispanic whitesCox proportional regression modelMedian overall survivalOutcomes of patientsNHB patientsMyelodysplastic syndromeNHW patientsHazard ratioHispanic patientsSurvival outcomesDisease characteristicsIncidence rateRace/ethnicityOverall survivalInsurance statusSurvival analysisAge groupsLonger median overall survivalLarge population-based analysisMultivariable Cox proportional regression modelsHigher incidence rate ratioEarlier population-based studies